CervoMed (NASDAQ:CRVO) Given Buy Rating at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of CervoMed (NASDAQ:CRVO) in a research report released on Monday,Benzinga reports. The brokerage currently has a $10.00 price target on the stock.

Other research analysts have also recently issued research reports about the stock. HC Wainwright cut shares of CervoMed from a “buy” rating to a “neutral” rating in a report on Tuesday, December 17th. Morgan Stanley restated an “underweight” rating on shares of CervoMed in a report on Wednesday, December 11th. Jones Trading upgraded shares of CervoMed from a “hold” rating to a “buy” rating and set a $15.00 target price for the company in a report on Thursday, March 13th. Roth Capital upgraded shares of CervoMed to a “strong-buy” rating in a report on Thursday, December 5th. Finally, Roth Mkm increased their target price on shares of CervoMed from $7.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday, March 11th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $25.75.

CervoMed Price Performance

Shares of CRVO stock opened at $9.05 on Monday. The firm has a fifty day moving average of $2.59 and a 200-day moving average of $7.93. CervoMed has a 12-month low of $1.80 and a 12-month high of $26.38.

Hedge Funds Weigh In On CervoMed

Several large investors have recently modified their holdings of CRVO. Woodline Partners LP bought a new position in shares of CervoMed in the fourth quarter valued at about $175,000. Perigon Wealth Management LLC bought a new position in shares of CervoMed in the fourth quarter valued at about $147,000. State Street Corp raised its position in shares of CervoMed by 28.1% in the third quarter. State Street Corp now owns 104,456 shares of the company’s stock valued at $1,525,000 after purchasing an additional 22,903 shares during the period. Nuveen Asset Management LLC raised its position in shares of CervoMed by 113.6% in the fourth quarter. Nuveen Asset Management LLC now owns 41,569 shares of the company’s stock valued at $97,000 after purchasing an additional 22,104 shares during the period. Finally, Cornerstone Wealth Management LLC bought a new position in shares of CervoMed in the fourth quarter valued at about $48,000. 25.15% of the stock is owned by institutional investors.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.